Spero Therapeutics, Inc. (SPRO) - Form 8-K Summary
Business Context and Reporting Period
Spero Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 12, 2026. The filing announces the Company's financial results for the second quarter ended June 30, 2026. The Company is headquartered in Cambridge, Massachusetts, and its common stock trades on The Nasdaq Global Select Market under the symbol "SPRO."
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in this specific filing text, as the document only confirms the issuance of the Q2 2026 results announcement.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information contained in Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. No specific guidance, outlook, management commentary, risks, or unusual items are described within the text of this 8-K form.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of any outstanding debt or financing arrangements referenced in the full financial disclosure.